PBT.AX - Prana Biotechnology Limited

ASX - ASX Delayed Price. Currency in AUD
0.044
0.000 (0.00%)
At close: 3:59PM AEDT
Stock chart is not supported by your current browser
Previous Close0.044
Open0.043
Bid0.039 x 0
Ask0.044 x 0
Day's Range0.042 - 0.044
52 Week Range0.041 - 0.078
Volume199,256
Avg. Volume58,264
Market Cap23.627M
Beta (3Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-0.015
Earnings DateMar 4, 2016 - Mar 5, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.75
  • Simply Wall St.last month

    How Financially Strong Is Prana Biotechnology Limited (ASX:PBT)?

    Prana Biotechnology Limited (ASX:PBT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PBT Read More...

  • Business Wirelast month

    Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

    Prana Biotechnology Ltd (PBT.AX) (PRAN) today announced further pre-clinical evidence for PBT434 will be presented in a poster at the International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong on Sunday, October 7th, 2018 at 1:45pm.

  • Business Wire4 months ago

    PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

    Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today announced it will be presenting further pre-clinical evidence for PBT434 at the International Congress of Parkinson’s Disease and Movement Disorders® to be held in Hong Kong from October 5-9, 2018. The data to be presented will include new in-vivo evidence of the efficacy of PBT434 to prevent neuron loss and improve function in an animal model of Multiple system atrophy (MSA), an important cause of atypical Parkinsonism. MSA is a rapidly progressive and devastating neurological disease with no established treatments and is one of the target indications for PBT434.

  • Business Wire5 months ago

    First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

    Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases. The trial conducted in Melbourne, Australia is recruiting and dosing healthy adult and elderly volunteers, to ascertain the optimal drug dose.

  • Business Wire5 months ago

    Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

    Prana Biotechnology Ltd is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.